leisure time -WSS

leisure time

author：explore 2025-10-01 21:36:41 - browse：415

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Take antibiotics after sex, CDC recommends for certain risk groups

WSS

Activists slam private health insurers over coverage restrictions

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Trump demands the U.S. pay no more for drugs than other countries … again

How one medical school became remarkably diverse

BD to buy Edwards patient monitoring unit for $4.2 billion

After affirmative action ruling, medical educators look to 'holistic review'

focus

leisure time

focus

Activists slam private health insurers over coverage restrictions

Anesthesiologist group: stop taking Ozempic before surgery

Activists slam private health insurers over coverage restrictions

George Santos makes 1st court appearance after pleading not guilty to 13 counts

As demand for Covid shots wanes, Moderna seeks its next success

'Little Tech' descents on D.C., wanting a say in how AI is regulated

After affirmative action ruling, medical educators look to 'holistic review'

At least 13 dead in Texas as scorching temps continue

The high cost of giving birth even with insurance

George Santos makes 1st court appearance after pleading not guilty to 13 counts

focus

What does generative AI mean for health care? We asked experts

In Memoriam: Notable people who died in 2023

CMS got Medicare Advantage quality rating wrong, judge rules

An outdated Medicare rule harms dementia patients with anxiety

An outdated Medicare rule harms dementia patients with anxiety

At least 13 dead in Texas as scorching temps continue

focus

entertainment

focus

focus